Impax, J&J clash over Concerta ANDA, Watson gains certainty with its J&J deal
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Alza unit has sued Impax Laboratories in federal court, seeking to halt Impax from marketing a generic version of the attention-deficit hyperactivity disorder treatment Concerta (methylphenidate HCl extended release) before a US patent expires in 2018 and connected to the extended-release 54mg tablets. Meanwhile, the market has adjusted to Watson's 2 November announced deal on generic Concerta with J&J, under which Watson will launch a J&J-supplied authorised generic in 2011, with rights to continue selling the authorised generic through 2014.